Talk:Quinolinic acid

Professor Burdo's Introduction to Neuroscience class at Boston College is aiding in an initiative by the Society for Neuroscience to improve Wikipedia's coverage of a variety of Neuroscience topics.

User:Figueredo, User:T_Doh and User:Mannintg will be editing the page over the next several days and weeks —Preceding undated comment added 15:37, 4 November 2012 (UTC)

Review

Great job! I have just a few suggestions/questions for you. You mention in the "Clinical Implications" subsection "Mood Disorders" that QA is implicated in schizophrenia. Are their any prevailing hypotheses about this you could mention? In the "Clinical Implications" section, the evidence for the role of QA in some of the diseases, such is ischemia, appears to come from primary sources (a single experiment); are there any other experiments that reinforce the correlation between QA and brain ischemia? Referencing more than one so as to present a balanced viewpoint would be beneficial. Also, be careful about spelling/grammar/capitalization mistakes. For example: “A loss of astrocytes results in a pro-inflammatory effect, further increasing the initial inflammatory response the quinolinic acid was produced by" -- this sentence (in the "Toxicity" section) should be rearranged so that it doesn't end in a preposition. Be consistent with your capitalization in section headings as well. Reedich (talk) 05:33, 29 November 2012 (UTC)

Made capitalization in headings consistent, and sentence in toxicity section was corrected. Further proofreading was done to correct spelling, grammar, and capitalization mistakes. Jackie will address your questions regarding clinical implications section. Thanks! T Doh (talk) 20:48, 2 December 2012 (UTC)

Reedich, thank you for your feedback. The reason why I did not originally include more information about how quinolinic acid is involved in schizophrenia is because not much is known about quinolinic acid's role in this disorder. Other parts of the kynurenine pathway play a role in schizophrenia. Because quinolinic acid interacts with many of the parts of this pathway that appear to be involved in schizophrenia, it seems as though quinolinic acid may too have a part in this disorder. However, there has not been any research done about how quinolinic acid is associated with schizophrenia. Instead of just stating that quinolinic acid may be associated with schizophrenia, I added a whole section explaining the reasoning as to why it might be involved. For brain ischemia, I added two other experiments to make it more clear how quinolinic acid and this condition are related. I took your suggestion to add more sources very seriously and added more detail and sources to most of the other sections in the clinical implications section. Figueredo (talk) 03:13, 4 December 2012 (UTC)

Peer Review for BI481

I think you have made a very in depth Wikipedia page for your topic. It successfully describes the mechanisms involved in the production of QUIN and relates it to toxicity in the cells under certain circumstances. I think the “Clinical Implications” sections is your best section because each description is short and clear. This section clearly shows the variety of important functions of QUIN.

I think your “History” section seems to be a little too short/lacking. I understand there might not be a lot of information on the history but a little more information (experiments, any substantial research) could make this section stronger. I also think the introduction of “Schwarcz” is a little awkward – a first name or a year or a title might help.

I think the decomposition of QUIN does not need to be in the introductory section because it seems to be just placed in there without a clear reason as to why. Is this decomposition important in a biological mechanism in the body?

And I think you can always go through the page and create more hyperlinks because information with such heavy and specific details always requires a lot of background knowledge and these hyperlinks help to clarify hard concepts.

Does QUIN serve any other function besides biological ones (is QUIN found in the environment or in other animals?)

Overall – a very good page and it was hard to find many things to improve on. Pictures area always helpful (mechanism of QUIN, pictures of parts of the brain you are specifically referring to, the kynurenine pathway of tryptophan). Plavadera (talk) 22:45, 18 November 2012 (UTC)

There is not much more to be said about the history section. The rest of the page gives information about the ongoing research on the topic and important discoveries of quinolinic acid's relationship to clinical disorders. In the biologically based literature we read there is nothing mentioned of QA outside of its neurotoxic effects. A picture of the kynerein pathway was added to give more visual stimulus. Other edits and suggestions were addressed through editing Mannintg (talk) 18:21, 2 December 2012 (UTC)

This is a well written and well covered page. The chemical background is characterized in an affective manner. The commenter above stated a removal within the introduction; I disagree. I believe it offers a simple and specific overview of the page, as it should. It is difficult to imagine the pathways if one is unfamiliar with neuroscience. I noticed about one or two capitalization errors within the Toxicity section. The Toxicity section however is the most important to focus on, giving a connector between the history and production with the clinical significance. It is oddly noticeable how the hyperlinks start to disappear as you get further into the page, especially noticeable in the Treatment focus section. With the synthesis of QUIN in a laboratory, is it used to change conditions in the body? It just seems that it have an increasingly negative discussion around it. Also, as stated above, it would be good to look into natural substances that have been used either to breakdown QUIN or just further presence of QUIN elsewhere. The Clinical implications sections covers a lot, which is good, and it is covered in minimal words. Overall, very good. Well organized and topic covered fully. Maybe just take a read through it again and find one or two new papers to reference (new info). MURTAGH.KEVIN (talk) 02:15, 19 November 2012 (UTC)

A picture was added to help with understanding the kynurein pathway. In the treatment focus section there is mention of different molecules used to inhibit QA production. The research on QA focuses on its role as a neurotoxin, thus the "negative discussion around it".Mannintg (talk) 18:21, 2 December 2012 (UTC)

More hyperlinks were added to the page, especially in the treatment focus section as you suggested, errors in capitalization, grammar, and spelling were corrected. Thanks! T Doh (talk) 20:54, 2 December 2012 (UTC)

MURTAGH.KEVIN, I took your suggestion to add new information from new sources very seriously and added more detail and sources to almost all of the the sections in the clinical implications section. Thank you for your feedback. Figueredo (talk) 03:16, 4 December 2012 (UTC)

TRP?

What's TRP? Tryptophan? --Rifleman 82 (talk) 00:18, 19 November 2012 (UTC)

Yup. I have changed it to tryptophan. :)--MrADHD | T@1k? 00:23, 19 November 2012 (UTC)

That's great, thanks. --Rifleman 82 (talk) 00:43, 19 November 2012 (UTC)

Peer Review

This is a very well written article; there are just a few things I would like to discuss:

• Concise introduction, it flows smoothly and gives a good introduction of QA. I am just a little confused when I read the first sentence of the third paragraph. I understand that Norharmane suppresses the production of QA, but did you mean to place ‘through or by’ after the comma? So it reads “Norharmane, suppresses the production of QA, through 3-hydroxykynurenine and nitric oxide synthase, thereby acting as a neuroprotectants.”
• Great graph/picture next to your introduction. Please check to make sure the ChEMBL is the correct value.
• The source used for the history section is not necessarily regarded as a review; the author claims his article is a ‘minireview series review.’ I am sure you have discussed this as a group, but please make sure that the article falls under the correct source requirements.
• Regarding the second sentence under the Synthesis section, I am a little confused on which compound you are referring too. If you could name the compound that is commercially available, it would make the section flow more smoothly. Great pictures for this section
• Regarding the third sentence in Production in vivo, you need to capitalize the Q in QA.
• The first few sections under the clinical implication section need to be expanded. Maybe you could find more information on schizophrenia and create another section. There is little new information provided under the conditions related to neuronal death section. The ALS section has good information, just proofread. Use some commas in the Brain ischemia section.
• The HIV and AIDS section is really good. I would not redirect the word cell, in cell death, though.
• For the treatment focus section, if you are going to signify that Kyurenic acid is abbreviated as KYA, it should be referred to as KYA throughout the section.

Overall, this is a very interesting article that includes a lot of good information and great pictures. There is some research that needs to be done, specifically for the clinical implication section, but the other sections are very close to being completed. Check to make sure all of your sources follow our guidelines. When you are finished, just make sure to proofread your article and double check the capitalizations. Best, BlakePierce (talk) 16:38, 19 November 2012 (UTC)

Blake, Norharmane suppresses all three; QA, 3-hydroxykynurenine and nitric oxide synthase, thereby acting as a neuroprotectant. The ChEMBL is the correct value. All mention of QA were changed to quinolinic acid to maintain consistency. Conditions related to neuronal death was adjusted to be less repetitive. The KYA comment was also corrected regarding the treatment focus section. Capitalization and further proofreading was completed. The other critiques will be addressed by Jackie. Thanks for the help! T Doh (talk) 21:03, 2 December 2012 (UTC)

BlackPierce, The history citation was not overlooked. The FEBS Journal published a series of review articles about quinolinic acid in the issue and the citation we used came from the introduction to that series. Also, the author of the article you question wrote one of the review articles in that series. Thus, it is a fully credible and useful source. I agreed with your critique of the mood disorders sections, so I did some reorganizing. I created the psychiatric disorders section and separated out mood disorders and schizophrenia. In addition, I expanded on schizophrenia. I proofread the sections following your advice. Finally, I took your suggestion to add new information from new sources very seriously and added more detail and sources to almost all of the the sections in the clinical implications section. Figueredo (talk) 03:26, 4 December 2012 (UTC)

2

This article has obviously been extremely well researched and contains a lot of revelant information. The article is also written in good scientific form. The information on the panel to the right is relevant and informative. This work is off to a great start.

I have only a few criticisms:

• In the first section, you mention Cox-2 inhibitors. Cox-2 inhibitors are FDA approved medical interventions. What are medical names and what are they used to treat? COX-2 Inhibitor
• How did L. Henderson describe the compound initially?
• In the synthesis section, you mention the compound is commercially available. What companies sell this compound?
• If possible, a schematic for “production in vivo” or “toxicity” would be very helpful due to the highly technical description of these mechanisms
• For clinical implications, are there any epidemiological studies?
• Are there any genetic (OMIM) information on quinolinic acid disorders?
• A section of current research with quinolinic acid would improve the article

BSByrne (talk) 22:41, 19 November 2012 (UTC)

More specific information about COX-2 inhibitors was added in the treatment focus section. A schematic for "production in vivo" was added. The pictures associated with "toxicity" were all copyrighted and thus could not be used. For more visuals, refer to the cited reviews on QA. Your question about genetics is relevant, and there does not appear to be a well studied genetic linkage to the production of QA, though proteins like IDO and TDO which are crucial to the production of QA are currently under investigation for their correlation to the disorders mentioned. Mannintg (talk) 18:41, 2 December 2012 (UTC)

BSByrne, We added in one of the names for Cox-2 inhibitors, licofelone, and what they are used to treat. We did not feel the need to descibre how L. Henderson originally descibed quinolinic acid, because the emphasis in the history section is more on the timeline. Furthermore, what is more important is the current description of quinolinic acid given throughout the paper. We did not feel that is was necessary to mention which companies you can purchase quinolinic acid from, as we do not have the expertise to recommend one company over another. Also, another current editor of the page not affiliated with Boston College wrote this section. There are no epidemiological studies. I think that much of the current research is discussed in the section Treatment Focus. Thank you for your feedback. Figueredo (talk) 03:37, 4 December 2012 (UTC)

Please note that there is a HUGE time change difference between when we posted things and the time Wikipedia records. The current time is 2:25 pm Figueredo (talk) 19:25, 10 December 2012 (UTC)

Crystal structure

In case anyone (including me) wants to make a 3D structure of this molecule, its crystal structure has been reported: Y.-T. Wang et al., Acta Cryst. E (2006) 62, o1496-o1497. --Ben (talk) 11:12, 27 April 2016 (UTC)

Chemical antagonist hyperlink

The 'antagonist' hyperlink goes to the article of a literary antagonist instead of the correct receptor antagonist. The page is protected and I can't edit it. CracksInTheFloor (talk) 13:50, 25 October 2022 (UTC)